Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan

Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan

Abstract Introduction Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder affecting several organs, including skin. We sought to assess the real-world effectiveness and safety of a topical sirolimus 0.2% gel treatment for TSC-related cutaneous manifestations. Methods We co...

Full description

Bibliographic Details
Main Authors: Akemi Egami, Shinji Takahashi, Takeshi Kokubo, Sreedevi Boggarapu, Eric Beresford
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Series:Dermatology and Therapy
Subjects:
Angiofibroma
Effectiveness
Adverse events
Adverse drug reactions
Mechanistic target of rapamycin inhibitors
Patient satisfaction
Online Access:https://doi.org/10.1007/s13555-023-00914-2

Internet

https://doi.org/10.1007/s13555-023-00914-2

Similar Items